XOMA’s (XOMA) “Buy” Rating Reaffirmed at HC Wainwright

XOMA (NASDAQ:XOMA)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $104.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 397.85% from the stock’s previous close.

Separately, StockNews.com downgraded shares of XOMA from a “hold” rating to a “sell” rating in a research report on Tuesday, February 25th.

XOMA Price Performance

XOMA stock opened at $20.89 on Wednesday. The firm has a market cap of $246.15 million, a price-to-earnings ratio of -6.00 and a beta of 1.00. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. XOMA has a 12-month low of $19.92 and a 12-month high of $35.00. The company’s fifty day simple moving average is $24.64 and its 200 day simple moving average is $27.29.

XOMA (NASDAQ:XOMA) last released its earnings results on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.17). XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. The firm had revenue of $8.70 million during the quarter, compared to analyst estimates of $8.75 million. On average, analysts expect that XOMA will post -1.41 earnings per share for the current year.

Insiders Place Their Bets

In other XOMA news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the business’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $26.10, for a total value of $13,069,366.20. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 7.20% of the stock is currently owned by insiders.

Institutional Trading of XOMA

A number of institutional investors have recently modified their holdings of the business. Woodline Partners LP increased its holdings in shares of XOMA by 63.9% in the 4th quarter. Woodline Partners LP now owns 156,266 shares of the biotechnology company’s stock worth $4,107,000 after buying an additional 60,927 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of XOMA by 238.9% in the 4th quarter. JPMorgan Chase & Co. now owns 12,089 shares of the biotechnology company’s stock worth $318,000 after buying an additional 8,522 shares during the last quarter. Barclays PLC increased its holdings in shares of XOMA by 300.7% in the 3rd quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after buying an additional 8,447 shares during the last quarter. Los Angeles Capital Management LLC bought a new position in shares of XOMA in the 4th quarter worth $206,000. Finally, Renaissance Technologies LLC increased its holdings in shares of XOMA by 89.8% in the 4th quarter. Renaissance Technologies LLC now owns 16,100 shares of the biotechnology company’s stock worth $423,000 after buying an additional 7,619 shares during the last quarter. 95.92% of the stock is currently owned by hedge funds and other institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.